Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Threshold Issues Updated Results From Phase 2 Study Of TH-302 - Quick Facts

RELATED NEWS
Trade THLD now with 

Threshold Pharmaceuticals, Inc. (THLD: Quote) announced updated results from a Phase 2 study of TH-302, the company's investigational hypoxia-targeted drug, in patients with soft tissue sarcoma, including additional results from patients who were administered TH-302 as single agent maintenance therapy following induction with TH-302 in combination with doxorubicin.

In the single-arm Phase 2 component of the study, previously untreated patients with metastatic or locally advanced unresectable soft tissue sarcomas were treated with TH-302 and doxorubicin for a maximum of six cycles. After six cycles, patients with stable disease, partial or complete responses, and with acceptable toxicity, were eligible to receive TH-302 maintenance therapy. Response was assessed using RECIST criteria.

In overall study population, results for the 91 patients in the Phase 2 component of the study include median progression free survival of 6.7 months, median overall survival of 21.5 months, one-year survival of 73% and two-year survival of 44% and overall best response of 36%.

The company also reported results for TH-302 single agent maintenance therapy population. The median number of treatment cycles with TH-302 was 4.0. Median PFS was 3.7 months. Median overall survival was 18 months. Overall best response was 54%.

Register
To receive FREE breaking news email alerts for Threshold Pharmaceuticals Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Stocks are showing a lack of direction in early trading on Friday after ending the previous session sharply higher. The major averages have been bouncing back and forth across the unchanged line, unable to sustain any significant moves. While the Commerce Department released a report on Friday showing a modest increase in new home sales in the U.S. in the month of September, the uptick came from a significantly downwardly revised level in August. The terrorist group known as the Islamic State in Iraq and the Levant (ISIL) is earning about $1 million each day by smuggling oil out of the Middle East, according to the US Treasury Department. Speaking at the Carnegie Endowment for International Peace on Thursday, Under Secretary for Terrorism and Financial Intelligence David Cohen said "ISIL has raised a significant amount of its money - many
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.